Circulating Tumor Cells Market Report 2026

Circulating Tumor Cells Market Overview

• Circulating Tumor Cells market size has reached to $13.27 billion in 2025 • Expected to grow to $23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: Rising Cancer Incidence Drives Surge In Circulating Tumor Cells Market • Market Trend: Innovations in Circulating Tumor Cell Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Circulating Tumor Cells Market?

Circulating tumor cells refer to solid tumor-derived cells that have shed from the primary tumor and are extravasated into the blood circulation system. They are used as a tool to diagnose and prognosis of cancer. The main products of circulating tumor cells include kits and reagents, blood collection tubes and devices or systems. Kits and reagents are a complete set of consumables that include a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. They are collected using different specimens of a human body including blood, bone marrow and other body fluids by using different technologies such as CTC enrichment, CTC detection and CTC analysis that are used for clinical or liquid biopsy and research applications.

What Is The Circulating Tumor Cells Market Growth Forecast?

The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of personalized oncology diagnostics, rising investments in cancer biomarker research, expansion of automated cell capture technologies, growing demand for early-stage cancer detection tools, increasing integration of ai in oncology diagnostics. Major trends in the forecast period include increasing use of liquid biopsy techniques, rising adoption of microfluidic ctc isolation devices, growing integration of automated ctc analysis systems, expansion of oncology research applications, enhanced focus on early cancer detection.

Global Circulating Tumor Cells Market Segmentation

1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems 2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis 3) By Application: Clinical Or Liquid Biopsy, Research Subsegments: 1) By Kits And Reagents: Cell Enrichment Kits, Detection Kits, Nucleic Acid Isolation Kits 2) By Blood Collection Tubes: Standard Blood Collection Tubes, Specialized Blood Collection Tubes 3) By Devices Or Systems: Microfluidic Devices, Automated Cell Capture Systems, Imaging Systems

What Is The Driver Of The Circulating Tumor Cells Market?

The growing incidence of cancer is expected to propel the circulating tumor cells market growth going forward. Cancer refers to a disease in which a few body cells grow uncontrollably and spread to other parts. Circulating tumor cells are used to help in the early detection and diagnosis of cancer, and thus growing incidence of cancer propels the growth of the circulating tumor cells market. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing incidence of cancer is driving the growth of the circulating tumor cells industry.

Key Players In The Global Circulating Tumor Cells Market

Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc.

Global Circulating Tumor Cells Market Trends and Insights

Major companies operating in the circulating tumor cells (CTC) market are focusing on developing innovative solutions, such as biomarker-specific CTC assays, to meet the rising demand for precise, non-invasive cancer diagnostics and advanced personalized therapy monitoring. Biomarker-specific CTC assays enable the detection and characterization of circulating tumor cells based on specific protein expression, offering more detailed phenotypic information than traditional CTC enumeration methods, which mainly provide total cell counts without biomarker differentiation. For instance, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics company, introduced the CELLSEARCH CTC test with the DLL3 biomarker, now available as a Research Use Only (RUO) service in North America and Europe. The assay leverages the FDA-cleared CELLSEARCH platform to detect circulating tumor cells expressing DLL3, a protein overexpressed in aggressive small-cell lung cancer (SCLC) and neuroendocrine tumors. By focusing on DLL3, the test enables phenotypic characterization of CTCs associated with poor prognosis, supporting biopharma research in developing targeted therapies. This innovation provides researchers with a non-invasive tool to study tumor heterogeneity, monitor disease progression, and evaluate response to targeted treatments.

What Are Latest Mergers And Acquisitions In The Circulating Tumor Cells Market?

In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition aims to enhance Cell Microsystems' capabilities in cell analysis and provide advanced solutions for research and clinical applications. Fluxion Biosciences is a US-based company, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).

Regional Outlook

North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Circulating Tumor Cells Market?

The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.